Exhibit 99.1

aegr2016b.jpg
AEGERION PHARMACEUTICALS ANNOUNCES
THIRD QUARTER 2016 FINANCIAL RESULTS

- Company records $35.4 million in total net product sales --

Cambridge, MA, November 3, 2016 -
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business update for the third quarter of 2016.

Highlights

Aegerion recorded total net product sales of $35.4 million in the third quarter of 2016.
Aegerion recorded $13.4 million in net product sales of MYALEPT® (metreleptin) for injection in the third quarter of 2016, $11.9 million, or 89% of which was from prescriptions written in the United States (U.S.). Net product sales in the third quarter include a $1.0 million sale of inventory to Shionogi for distribution in Japan, South Korea and Taiwan.
As of September 30, 2016, there were approximately 125 active generalized lipodystrophy (GL) patients on commercial therapy, approximately 101 of whom are U.S. patients. In the third quarter, Aegerion began adding GL patients on commercial MYALEPT via named patient sales programs in Germany, Israel and Italy.
Aegerion recorded $22.0 million in net product sales of JUXTAPID® (lomitapide) capsules in the third quarter of 2016, $18.6 million, or 85% of which was from prescriptions written in the U.S. As of September 30, 2016, there were approximately 393 active patients on JUXTAPID therapy globally, approximately 260 of whom are U.S. patients.
In September 2016, Japan’s Ministry of Health, Labor & Welfare (MHLW) granted approval for JUXTAPID in Japan for the treatment of homozygous familial hypercholesterolemia (HoFH).
Aegerion expects to complete its merger with QLT Inc. and to submit a marketing authorization application (MAA) for metreleptin as a potential treatment for GL and a subset of partial lipodystrophy (SPL) patients in the EU in the fourth quarter of 2016.

Chief Executive Officer Mary Szela commented, “We continue to make significant strides toward reinvigorating Aegerion and returning to growth. In the third quarter, we strengthened the commercial pillars of our business, particularly through MYALEPT. We have initiated a stronger emphasis on the education of physicians to assist in identifying appropriate GL patients eligible for metreleptin therapy. We were also encouraged to see the rate of JUXTAPID patient attrition due to PCSK9 inhibitors continue to stabilize, reinforcing our belief that there exists a core base of adult HoFH patients for whom JUXTAPID will remain a crucial therapy.”



The following information was filed by Aegerion Pharmaceuticals, Inc. (AEGR) on Thursday, November 3, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aegerion Pharmaceuticals, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account